A study of adults with PKP2-linked arrhythmogenic cardiomyopathy
Part of Genetic & congenital, Heart & circulation clinical trials.
This study follows people with a confirmed PKP2 genetic mutation and arrhythmogenic cardiomyopathy (ACM) to understand how their condition changes over time. It may help doctors learn more about the disease and plan future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 or older) with a doctor-confirmed diagnosis of arrhythmogenic cardiomyopathy (ACM).
- You must have a specific harmful change (called a truncating mutation) in the PKP2 gene.
- You have frequent extra heartbeats (premature ventricular contractions or PVCs).
- You must already have an implantable cardioverter-defibrillator (ICD) placed before joining.
- For Part A: your heart's pumping ability (LVEF) needs to be 50% or higher. For Part B: it needs to be 40% or higher.
- You cannot have another harmful genetic change linked to ACM, a history of certain other heart problems, severe heart failure symptoms (Class IV), or prior gene therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows participants who have already received the gene therapy LX2020 for a genetic heart condition called arrhythmogenic cardiomyopathy. It tracks their long-term safety and health outcomes, with no new treatment given.
This trial evaluates early prevention and treatment strategies for arrhythmogenic cardiomyopathy (ACM), a heart condition that can cause abnormal heart rhythms. It aims to improve care by using advanced tests like heart imaging and genetic sequencing to guide treatment.
This study looks at how arrhythmogenic cardiomyopathy develops, how doctors can better diagnose it, and what it may mean for a person’s future risk. Because the study focuses on people with known genetic causes, it may help improve understanding for patients and families with this condition.
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
This study is for people with a specific genetic heart condition (PKP2-related arrhythmogenic cardiomyopathy) who already have an ICD. It does not test a new treatment but instead follows participants over time to learn more about the condition.
Hear when a new Arrhythmogenic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.